AnalysisAstraZeneca's 'Lab of the Future' Pitch Meets the Hard Part: Safety Prediction, and a Bispecific Biotech Burning CashVia News Editorial Team•Nov 8, 2026
AnalysisAstraZeneca's AI Drug-Design Vision Is Still a Forecast, While Oncology's Near-Term Catalysts Are ConventionalVia News Editorial Team•Oct 20, 2026
AnalysisAstraZeneca's AI-Designed-Biologics Pitch Is a Forecast, Not a Result: What the Oncology Pipeline Actually ShowsVia News Editorial Team•Oct 18, 2026
AnalysisAstraZeneca's AI-to-Lab Loop Meets a Crowded Oncology Calendar, and the Evidence for It Is Still ThinVia News Editorial Team•Oct 15, 2026
AnalysisAstraZeneca Says Its Data Will Train Better Cancer Drugs. Its Pitch Rests on a Source That Failed Our Check.Via News Editorial Team•Oct 13, 2026
AnalysisOncology's Q4 Catalyst Season Meets Pharma's AI Pitch: What Is Verified, and What Is Still a ClaimVia News Editorial Team•Oct 11, 2026
AnalysisAstraZeneca's AI 'Lab of the Future' Meets a Crowded Oncology Pipeline: What Is Proven, and What Is Still a PromiseVia News Editorial Team•Oct 10, 2026
AnalysisAI-Designed Biologics and Personalized mRNA Vaccines: What the Oncology Evidence Supports, and What It Doesn'tVia News Editorial Team•Oct 3, 2026